Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cyclerion Therapeutics (CYCN) Research & Development (2019 - 2025)

Cyclerion Therapeutics has reported Research & Development over the past 7 years, most recently at $348000.0 for Q3 2025.

  • Quarterly results put Research & Development at $348000.0 for Q3 2025, up 329.63% from a year ago — trailing twelve months through Sep 2025 was $496000.0 (up 95.28% YoY), and the annual figure for FY2024 was $286000.0, down 81.12%.
  • Research & Development for Q3 2025 was $348000.0 at Cyclerion Therapeutics, up from $56000.0 in the prior quarter.
  • Over the last five years, Research & Development for CYCN hit a ceiling of $12.1 million in Q2 2021 and a floor of $24000.0 in Q4 2023.
  • Median Research & Development over the past 5 years was $572000.0 (2023), compared with a mean of $3.3 million.
  • Biggest five-year swings in Research & Development: tumbled 97.96% in 2023 and later skyrocketed 329.63% in 2025.
  • Cyclerion Therapeutics' Research & Development stood at $10.5 million in 2021, then crashed by 88.76% to $1.2 million in 2022, then tumbled by 97.96% to $24000.0 in 2023, then surged by 133.33% to $56000.0 in 2024, then surged by 521.43% to $348000.0 in 2025.
  • The last three reported values for Research & Development were $348000.0 (Q3 2025), $56000.0 (Q2 2025), and $36000.0 (Q1 2025) per Business Quant data.